Phialogics is developing cell-type-specific immune checkpoint activators that rebalance the immune response to prevent multi-organ failure in autoimmune diseases. The company's biologics target the underlying immune imbalance that leads to conditions such as psoriasis and rheumatoid arthritis, offering a therapeutic alternative to traditional immune suppression.
Funding
$549.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases often rely on broad immunosuppression, which can lead to significant side effects and increased risk of infection. These therapies fail to address the underlying immune imbalance that drives autoimmune pathology, leaving a need for more targeted and effective approaches.
Solution
Phialogics is developing cell-type-specific immune checkpoint activators designed to rebalance the immune response and prevent multi-organ failure in autoimmune diseases. Their biologics aim to precisely modulate immune activity within specific cell populations, promoting immune homeostasis and resolving chronic inflammation. By targeting the root cause of immune dysregulation, Phialogics seeks to offer a therapeutic alternative to traditional, non-selective immunosuppressants. This approach aims to protect patient tissues from autoimmune attacks while minimizing systemic immune suppression.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases such as psoriasis and rheumatoid arthritis, as well as the physicians who treat them.
Features
- Cell-type-specific targeting of immune checkpoint pathways
- Biologic therapeutics engineered to rebalance the immune response
- Modulation of immune activity to resolve chronic inflammation
- Prevention of multi-organ failure in autoimmune diseases